Navigation Links
VIVUS to Participate in Three Investor Conferences in September
Date:8/31/2011

MOUNTAIN VIEW, Calif., Aug. 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management, including Leland Wilson, Chief Executive Officer; Timothy Morris, Chief Financial Officer, and Wesley W. Day, Ph.D., Vice President, Clinical Development, will participate in three investment conferences during the month of September.  

The conference presentation schedule is as follows:

Stifel Nicolaus 2011 Healthcare Conference
Wednesday, September 7, 2011
8:00 a.m. ET
Four Seasons Hotel Boston
Boston, MA

UBS Global Life Sciences Conference
Tuesday, September 20, 2011
2:00 p.m. ET
Grand Hyatt New York
New York, NY

Sixth Annual JMP Securities Healthcare Conference
Wednesday, September 28, 2011
12:00 p.m. ET
St. Regis New York
New York, NY

A live audio webcast and an archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Offi
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
(Date:8/18/2014)... with unprecedented efficiency and data storage may ... built-in electric polarizations to read and write ... popular data-driven technology. But ferroelectrics must first ... a curious habit of "forgetting" stored data. ... Department of Energy,s Brookhaven National Laboratory have ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/16/2014)... (PRWEB) August 16, 2014 Firms ... industry provide guidance and advisory services to businesses, ... technical issues. Industry services are highly diverse as ... industry services range from geological and geophysical consulting ... “Consequently, over the past five years, the recovery ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... CHICAGO and HOBOKEN, N.J. , Aug. 2 ... Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & ... program supports clinical or pre-clinical research focused on human protein therapies in hematology, ... , , ...
... 2 Tengion Inc. (Nasdaq: TNGN ) ... the position of Chief Financial Officer.  Mr. Davis comes to Tengion after ... to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, ... , , ...
... LAUSANNE , Switzerland , August 2, 2010 ... its Global Films,business to Bilcare AG, one of the world,s leading providers ... . The agreement brings together complimentary capabilities and,synergy,s of two leading global ... ...
Cached Biology Technology:Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 3
(Date:8/19/2014)... made to decrease China,s increasing caesarean section rate, suggests ... BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) ... delivery rates in the world. Of 16 million babies ... the exact rate is not known, the current Chinese ... caesarean rates ranging from 36% to 58%. However, before ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... the Younger Dryas interval, which saw a rapid return ... it has been assumed that cooling temperatures and their ... groups. David Meltzer from the Southern Methodist University ... of Arizona in Tucson, USA, suggest otherwise in their ...
... MADISON, WI, April 12, 2010-What do obesity trends ... in Kenya, or alternative soil conservation strategies in Peru ... food and agriculture issues, and represent the world,s interdependence ... to build experiences of a broad and diverse world, ...
... Researchers at the Walter and Eliza Hall Institute have ... the female hormones oestrogen and progesterone, a finding that ... and treatments for breast cancer. The discovery, by ... Bioinformatics divisions, also explains decades of evidence linking breast ...
Cached Biology News:Bringing the world of agriculture to the classroom 2Hormone sensitivity of breast stem cells presents drug target 2
... Immunogen: synthetic peptide corresponding to the third ... dopamine receptor, conjugated to KLH. The immunizing ... and mouse gene. Physical form: Solution ... 0.01% sodium azide. Titertest method: IHC ...
Canine Chondrocytes (CnC) (500,000 cells)...
... Fluorescein 6-Fam, Hex, Tet Cy3, ... Fluorescein Tamra Black Hole Quenchers Molecular ... Tet Tamra, Joe 3 Dabcyl ... New York Double labelled probes are purified ...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Biology Products: